Full-Time

Senior Frontend Software Engineer

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Sant Cugat del Vallès, Barcelona, Spain

On-site commitment of three days a week.

Category
Frontend Engineering
Software Engineering
Required Skills
React.js
Redux.js
TypeScript
Axios
REST APIs
Requirements
  • Proficiency in React, React Router, State management using Redux or similar.
  • Experience working with Axios or similar.
  • Experience building microfrontends.
  • Restful API development and integration.
  • Solid understanding of HTML5 and CSS3.
  • Understanding of React performance techniques (memoization, lazy loading) and browser tools for debugging.
  • Experience with Typescript.
  • Strong understanding of software development principles, such as object-oriented programming and Agile methodologies.
  • 6+ years of professional experience in software development.
Responsibilities
  • Building and maintaining frontend interfaces for our applications.
  • Writing reusable, modular React components.
  • Collaborating with other engineers, product owners, and stakeholders to refine features and ensure they deliver outcomes.
  • Implementing responsive designs.
  • Troubleshooting, diagnosing, and resolving bugs and performance issues.
  • Participating in Agile ceremonies, such as daily stand-ups and sprint planning.
Desired Qualifications
  • Experience designing solutions for complex projects within large organizations.
  • Familiarity with common frontend libraries.
  • Experience with CI/CD tools, such as Azure DevOps or GitHub Actions.
  • Experience with Automated UI Testing, such as Selenium.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca stands out from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency.
  • Real-world evidence supports AstraZeneca's drug efficacy and safety demonstrations.
  • Personalized medicine complements AstraZeneca's focus on targeted therapies.

What critics are saying

  • AI tool for breast cancer screening may face effectiveness challenges.
  • Investment in Dunkirk may be affected by changes in French investment regulations.
  • Highly competitive pharmaceutical market requires constant innovation and regulatory compliance.

What makes AstraZeneca unique

  • AstraZeneca excels in Oncology, Cardiovascular, and Respiratory therapy areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing resources with the scientific community.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.

Delcade
Apr 4th, 2025
Foreign investment in France: Key trends, legal considerations (2024)

AstraZeneca invested €365 million in expanding its production lines in Dunkirk.